Purchase CD Products
FDALive Interactive CD Purchasing and Licensing Agreement: Please read before selecting this item
Federal law(Title 17 USC, Sections 501 and 506) provides severe civil and criminal penalties for unauthorized use of this product or service. Reproduction, distribution, redistribution and exhibition of FDALive products or services for other than office use is strictly forbidden. Criminal copyright infringements prosecuted by the Federal Bureau of Investigation, and may constitute a felony with a penalty of five years in prison and possible fines of US $250,000.
The product or service you are about to purchase is licensed to the purchasing organization for private use only, all other use is strictly prohibited, without the permission Of Video On Location, Inc.
All Rights Reserved. Copyright 1989-2009, Video On Location, Inc.
- Meeting of the Antimicrobial Drugs Advisory Committee
Meeting Date: 11/4/16-11/4/16
The committee will discuss new drug applications 209006 and 209007, solithromycin capsules and solithromycin for injection, sponsored by Cempra Pharmaceuticals, Inc., respectively for the proposed indication of treatment of community-acquired bacterial pneumonia (CABP).
|Location:||tbd||Related News Links:||Not Available|
- Microbiology Devices Panel of the Medical Devices Advisory Committee
Meeting Date: 11/9/16-11/10/16
On November 9, 2016, during session one, the committee will discuss and make recommendations regarding the reclassification of quantitative Cytomegalovirus (CMV) viral load devices from class III (Premarket approval) to class II (510(k)). A nucleic acid-based in vitro diagnostic device for the quantitation of CMV viral load, within the context of transplant patient management, is a post-amendment device classified into class III under section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act )(21 U.S.C. 360c(f)(1). To date, the following product code has been established for CMV viral load devices: PAB (CMV DNA Quantitative Assay). During session two, the committee will discuss and make recommendations regarding the appropriate initial classification for qualitative or quantitative viral load devices for Epstein-Barr virus, BK virus, JC virus, Human Herpesvirus 6, and Adenovirus infections. FDA is seeking expert recommendations to assess the potential risks and benefits of these devices when used in patients following solid-organ or stem cell transplantation.
|Location:||Gaithersburg Holiday Inn||Related News Links:||Not Available|
- Bone, Reproductive and Urologic Drugs Advisory Committee
Meeting Date: 12/6/16-12/6/16
The committee will discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving testicular function, including spermatogenesis.
|Location:||Tommy Douglas Conference Center||Related News Links:||Not Available|
- Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee
Meeting Date: 10/19/16-9/19/16
The committee will discuss the efficacy and safety of new drug application (NDA) 201656 (desmopressin), 0.75 mcg/0.1 mL and 1.5 mcg/0.1 mL nasal spray, submitted by Serenity Pharmaceuticals, LLC, for the proposed treatment of adult onset nocturia.
|Location:||tbd||Related News Links:||Not Available|
- Joint Anesthetic & Analgesic & DSRM Drug Adcomm
Meeting Date: 10/5/16-10/5/16
The committees will be asked to discuss naloxone products intended for use in the community, specifically the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in all ages, and the role of having multiple doses available in this setting. The committees will also be asked to discuss the criteria prescribers will use to select the most appropriate dose in advance of an opioid overdose event and the labeling to inform this decision, if multiple doses are available.
|Location:||FDA Meeting Room||Related News Links:||Not Available|
- General and Plastic Surgery Devices Panel
Meeting Date: 9/20/16-9/21/16
On September 20 and 21, 2016, the Committee will discuss and make recommendations regarding the classification of certain wound care products containing antimicrobials and other drugs as part of the routine process for device classification. These products are regulated under product code FRO, "Dressing, Wound, Drug," and are considered "pre-amendments" because they were in commercial distribution prior to May 28, 1976, when the Medical Devices Amendments were enacted, and have not yet been classified under section 513 of the Federal Food, Drug, and Cosmetic Act. As a part of the classification process, FDA is seeking committee input on the indications for use, risks to health, and safety and effectiveness of these wound care products, and how they should be classified. They may be classified in class I (general controls), class II (special and general controls), or class III (premarket approval (PMA), requiring demonstration of safety and effectiveness for each product). FDA believes some of these products may meet the definition of class II whereas others may meet the definition of class III in light of their intended use, composition, the extent of evidence of clinical benefit, and the risks they pose. For the subset of the these products that contain antibiotics, FDA appreciates the importance of appropriately addressing the risk of antimicrobial resistance (AMR) in light of the increasingly significant national public health concern posed by AMR. FDA is also aware of differences in the claims made for some products even though they may be regulated in the same manner.
|Location:||Gaithersburg, MD||Related News Links:||Not Available|